GENE ONLINE|News &
Opinion
Blog

2020-01-07| In-DepthInterviews

The Rejuvenated Promise of RNA Therapeutics

by Rajaneesh K. Gopinath
Share To
The field of RNA therapeutics is a budding one as compared to small molecules or protein therapeutics. Its recent surge must be attributed to the decades of work put into eliminating various drawbacks. “With a number of drugs in late-stage trials, the field is going to take off” says Dr. Judy Lieberman, Professor, Department of Pediatrics, Harvard Medical School. Since 2006, she also serves as an elected member of the Scientific Advisory Board for Alnylam Pharmaceuticals.

It's free! Log in now to read

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top